Significantly, unlike the Mnk inhibitors (CGP57380 and cercosporamide) and two clinically relevant retinoids (ATRA and 4-HPR) [35, 36], RRs show potent breast cancer cell growth inhibition and down-regulation of p-eIF4E. Here, EIF4E is linked to breast cancer.